<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04093882</url>
  </required_header>
  <id_info>
    <org_study_id>BHSkog</org_study_id>
    <nct_id>NCT04093882</nct_id>
  </id_info>
  <brief_title>The Relevance of the Blood-brain Barrier to Cognitive Dysfunction and Alzheimer's Disease</brief_title>
  <official_title>The Relevance of the Blood-brain Barrier to Cognitive Dysfunction and Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prof. Dr. med. Jochen Fiebach (Senior Physician)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study attempts to replicate the findings published in Nature Medicine by Nation and
      colleagues (2019). By using a large observational cohort (DZNE - Longitudinal Cognitive
      Impairment and Dementia Study; DELCODE) consisting of cognitively healthy individuals,
      individuals with subjective cognitive decline, mild cognitive impairment, and dementia due to
      Alzheimer's disease, an association between the blood-brain barrier and cognitive dysfunction
      is investigated. The integrity of the blood-brain barrier is investigated by using a novel
      MRI protocol as well as a novel biomarker in the cerebrospinal fluid.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Marker of blood-brain dysfunction using MRI</measure>
    <time_frame>1 day</time_frame>
    <description>Dynamic T1 contrast enhanced sequence using Gadovist</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Markers of blood-brain dysfunction using CSF</measure>
    <time_frame>1 day</time_frame>
    <description>Platelet-derived growth factor receptor-β in CSF</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Blood Brain Barrier</condition>
  <condition>Alzheimer Disease</condition>
  <condition>Cognitive Dysfunction</condition>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Healthy controls recruited through public advertisement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Siblings of people with Alzheimer's dementia</arm_group_label>
    <description>Siblings of people with Alzheimer's dementia recruited through public advertisement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjective cognitive decline</arm_group_label>
    <description>Individuals who subjectively experience cognitive decline but do not show deficits in age-, sex- and education-normed neuropsychological test results. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild cognitive impairment</arm_group_label>
    <description>Individuals who show deficits in neuropsychological test procedures but who do not exhibit substantial problems in daily life. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dementia due to Alzheimer's disease</arm_group_label>
    <description>Individuals diagnosed with dementia due to Alzheimer's disease by relying on anamnesis, neuropsychological test results, results of MRI and biomarkers found in the cerebrospinal fluid. Those individuals are part of the DELCODE cohort and were initially recruited in a memory clinic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Contrast agent enhanced MRI using Gadovist</intervention_name>
    <description>By using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.</description>
    <arm_group_label>Dementia due to Alzheimer's disease</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Mild cognitive impairment</arm_group_label>
    <arm_group_label>Siblings of people with Alzheimer's dementia</arm_group_label>
    <arm_group_label>Subjective cognitive decline</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Cerebro-spinal fluid
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        A description of the study population is provided by DZNE - Longitudinal Cognitive
        Impairment and Dementia Study (DELCODE).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        The eligibility criteria are defined by the study protocol from the observational study
        DZNE - Longitudinal Cognitive Impairment and Dementia Study (DELCODE).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Peter, Prod. Dr. med.</last_name>
      <phone>+49 30 450 517 628</phone>
      <email>oliver.peters@charite.de</email>
    </contact>
    <contact_backup>
      <last_name>Jochen Fiebach, Prof. Dr. med.</last_name>
      <email>jochen.fiebach@charite.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 13, 2019</study_first_submitted>
  <study_first_submitted_qc>September 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2019</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Oliver Peters</investigator_full_name>
    <investigator_title>Prof. dr. med. (Consultant Psychiatrist)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

